New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
13:55 EDTMEIPMEI Pharma files to sell 15.12M shares of common stock for holders
News For MEIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
16:15 EDTMEIPPoint72 Asset Management reports 7.2% passive stake in MEI Pharma
Subscribe for More Information
08:57 EDTMEIPMEI Pharma removed from Focus List at Roth Capital
Subscribe for More Information
December 12, 2014
09:13 EDTMEIPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Adobe (ADBE), up 5.5% after reporting first quarter results and that it will acquire Fotolia for approximately $800 in cash. ALSO HIGHER: ChemoCentryx (CCXI), up 107.1% after Phase II clinical trial in diabetic nephropathy with CCX140 met its primary endpoint... Oncothyreon (ONTY), up 15.8% after announcing exclusive agreement with Array BioPharma (ARRY)... Talisman Energy (TLM), up 24.4% after a report that Repsol (REPYY) is preparing to make a C$6.00 per share bid... GoPro (GPRO), up 4.4% after being upgraded to Overweight from Neutral at JPMorgan. LOWER: Emerald Oil (EOX), down 18% after cutting fiscal 2015 guidance, naming new COO, and providing an updated fiscal 2015 development plan... Goodrich Petroleum (GDP), down 8.2% after being downgraded to Underweight from Overweight at JPMorgan... MEI Pharma (MEIP), down 3.9% after 10M share Secondary priced at $4.00... Heritage-Crystal Clean (HCCI), down 6.6% after 3.1M share Secondary priced at $10.00.
08:02 EDTMEIPMEI Pharma 10M share Secondary priced at $4.00
The deal size was increased in size to 10M shares from 8.35M shares. BofA/Merrill acted as lead book running manager for the offering.
December 11, 2014
16:30 EDTMEIPOn The Fly: Closing Wrap
Subscribe for More Information
December 10, 2014
16:01 EDTMEIPMEI Pharma files to sell $45M shares of common stock
Subscribe for More Information
December 8, 2014
08:32 EDTMEIPMEI Pharma reports Phase II results of pracinostat
MEI Pharma reported significant clinical activity from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia. According to the presentation, 15 of 33 patients to date have achieved the primary endpoint of complete response plus complete response with incomplete blood count recovery plus morphologic leukemia-free state. No patient who achieved a clinical response has progressed. The combination of Pracinostat and azacitidine has been generally well-tolerated in the study, with no unexpected toxicities, with six subjects discontinued due to treatment-emergent adverse events. The study recently completed enrollment with a total of 50 patients, 17 of which are still too early for their initial clinical response assessment. The 60-day mortality rate, often used as an important benchmark in AML clinical studies, is approximately 10%. Currently, 14 patients have exceeded 90 days on study of which nine (64%) have achieved a CR, many evolving from a lesser earlier response. Pracinostat in combination with azacitidine was well tolerated in this population of elderly AML patients. The most common treatment-emergent adverse events included neutropenia, febrile neutropenia, thrombocytopenia, nausea, fatigue and anemia. Adverse events resulting in dose reductions were uncommon and frequently due to disease under study. Six patients to date have received study drug beyond 230 days, reflecting long-term tolerability.
08:32 EDTMEIPMEI Pharma reports Phase II results of pracinostat
Subscribe for More Information
08:05 EDTMEIPMEI Pharma data positive, says Stifel
Stifel believes that the data reported on MEI's Pracinostat for AML was "very promising." The firm thinks the positive AML results suggest that a trial of the drug as an MDS treatment should produce positive data next quarter. The firm keeps a Buy rating on the shares.
December 7, 2014
14:38 EDTMEIPMEI Pharma to hold an analyst and investor event
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use